IMMUNEONCO-B (01541) Reports Unchanged Share Capital for February 2026
Bulletin Express
Mar 05
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (Stock Code: 01541) issued a monthly return on movements in its securities for February 2026, confirming no changes in its share capital during the period. The total registered share capital remained at RMB 431.51 million, comprising 420.48 million H shares listed on the Hong Kong Stock Exchange and 11.03 million unlisted shares, each with a par value of RMB 1.
The company confirmed compliance with the minimum public float requirement for its H shares, maintaining the necessary threshold as prescribed by relevant listing rules. No share options, warrants, convertibles, treasury shares, or other arrangements were reported.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.